Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system [version 1; peer review: 4 approved]

Vasoactive intestinal peptide (VIP), a gut peptide hormone originally reported as a vasodilator in 1970, has multiple physiological and pathological effects on development, growth, and the control of neuronal, epithelial, and endocrine cell functions that in turn regulate ion secretion, nutrient abs...

Full description

Bibliographic Details
Main Authors:	Mari Iwasaki, Yasutada Akiba, Jonathan D Kaunitz
Format:	Article
Language:	English
Published:	F1000 Research Ltd 2019-09-01
Series:	F1000Research
Online Access:	https://f1000research.com/articles/8-1629/v1

id	doaj-bc6118f03f7147a581612e6d40017fdf
record_format	Article
spelling	doaj-bc6118f03f7147a581612e6d40017fdf2020-11-25T03:25:17ZengF1000 Research LtdF1000Research2046-14022019-09-01810.12688/f1000research.18039.119728Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system [version 1; peer review: 4 approved]Mari Iwasaki0Yasutada Akiba1Jonathan D Kaunitz2Greater Los Angeles Veterans Affairs Healthcare System, Los Angeles, CA, USADepartment of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USADepartments of Medicine and Surgery, UCLA School of Medicine, Los Angeles, CA, USAVasoactive intestinal peptide (VIP), a gut peptide hormone originally reported as a vasodilator in 1970, has multiple physiological and pathological effects on development, growth, and the control of neuronal, epithelial, and endocrine cell functions that in turn regulate ion secretion, nutrient absorption, gut motility, glycemic control, carcinogenesis, immune responses, and circadian rhythms. Genetic ablation of this peptide and its receptors in mice also provides new insights into the contribution of VIP towards physiological signaling and the pathogenesis of related diseases. Here, we discuss the impact of VIP on gastrointestinal function and diseases based on recent findings, also providing insight into its possible therapeutic application to diabetes, autoimmune diseases and cancer.https://f1000research.com/articles/8-1629/v1
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Mari Iwasaki Yasutada Akiba Jonathan D Kaunitz
spellingShingle	Mari Iwasaki Yasutada Akiba Jonathan D Kaunitz Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system [version 1; peer review: 4 approved] F1000Research
author_facet	Mari Iwasaki Yasutada Akiba Jonathan D Kaunitz
author_sort	Mari Iwasaki
title	Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system [version 1; peer review: 4 approved]
title_short	Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system [version 1; peer review: 4 approved]
title_full	Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system [version 1; peer review: 4 approved]
title_fullStr	Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system [version 1; peer review: 4 approved]
title_full_unstemmed	Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system [version 1; peer review: 4 approved]
title_sort	recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system [version 1; peer review: 4 approved]
publisher	F1000 Research Ltd
series	F1000Research
issn	2046-1402
publishDate	2019-09-01
description	Vasoactive intestinal peptide (VIP), a gut peptide hormone originally reported as a vasodilator in 1970, has multiple physiological and pathological effects on development, growth, and the control of neuronal, epithelial, and endocrine cell functions that in turn regulate ion secretion, nutrient absorption, gut motility, glycemic control, carcinogenesis, immune responses, and circadian rhythms. Genetic ablation of this peptide and its receptors in mice also provides new insights into the contribution of VIP towards physiological signaling and the pathogenesis of related diseases. Here, we discuss the impact of VIP on gastrointestinal function and diseases based on recent findings, also providing insight into its possible therapeutic application to diabetes, autoimmune diseases and cancer.
url	https://f1000research.com/articles/8-1629/v1
work_keys_str_mv	AT mariiwasaki recentadvancesinvasoactiveintestinalpeptidephysiologyandpathophysiologyfocusonthegastrointestinalsystemversion1peerreview4approved AT yasutadaakiba recentadvancesinvasoactiveintestinalpeptidephysiologyandpathophysiologyfocusonthegastrointestinalsystemversion1peerreview4approved AT jonathandkaunitz recentadvancesinvasoactiveintestinalpeptidephysiologyandpathophysiologyfocusonthegastrointestinalsystemversion1peerreview4approved
_version_	1724597798965346304

Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system [version 1; peer review: 4 approved]

Similar Items